Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06405607

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Iowa Health Care

Iowa City, Iowa, 52240, United States

Location status: Recruiting

Location contact

Lindsay E Golden

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Weight between 50kg and 150kg
  • No known allergies to rescue medication
  • For people capable of becoming pregnant, not pregnant and using contraception
  • Not currently breastfeeding
  • Meets criteria for DSM-V moderate to severe AUD.
  • Have at least 4 heavy drinking days (5 or more standard drinks in a day) in the past 30 days.
  • Not currently participating in formal treatment for AUD.
  • No history of a of cerebrovascular accident, asthma, or significant alcohol withdrawal history
  • No seizure disorder, coronary artery disease, heart failure, uncontrolled hypertension, insulin-dependent diabetes, pancreatitis, liver disease
  • No hallucinogen or ketamine use in past 12 months
  • No self-reported, personal, or familial history of specific psychotic disorders/episodes.
  • No serious traumatic brain injury (TBI) in the past 2 years
  • No substance use disorder other than AUD over the past 12 months
  • If taking a GLP-1 agonist, stable dosage for past 3 months
  • Family member/friend for pick-up, overnight post-drug session monitoring.
  • No MRI contraindications

Exclusion criteria

Drug/medication assessment that yields: nonprescription medication use, nutritional supplement, or herbal supplement (except when approved by the study investigators), medically unstable, current medication use that has significant potential to interact with study drug (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants, or benzodiazepines).

Psychiatric assessment that yields:1) history of severe suicide attempt, 2) current suicidality 3) first-degree relative with schizophrenia or schizoaffective disorder, 4) comorbid substance use disorder including cocaine, psychostimulant, or opioid use disorder within past 12 months 5) history of co-occurring psychotic episode/diagnosis including schizophrenia, schizoaffective disorder, schizophreniform, substance-induced psychosis, delusional disorder, or psychosis not otherwise specified, 6) high risk of adverse emotional or behavioral reaction based on the medical monitor's clinical evaluation that may also yield evidence of serious current stressors, a lack of meaningful social support, antisocial behavior, and/or serious personality disorders amongst other conditions.

Medical assessment that yields: serious ECG abnormalities (evidence of ischemia, myocardial infarction, QTc prolongation [QTc > .045]), serious abnormalities of complete blood count or chemistries, medical conditions that would preclude safe participation (significantly impaired liver function), or pregnancy.

MRI contraindication (pacemaker, etc.)

Treatment and study plan

Psilocybin

Drug

30 mg single dose

ketamine

Drug

0.75 mg/kg weight-based single dose

Primary outcomes

  1. Timeline Follow-Back for Alcohol to assess change

    Time frame: Weekly, over the course of 16 weeks

    Quantifies daily alcohol use

Secondary outcomes

  1. T1rho

    Time frame: Twice (before intervention, post intervention): at week 1 and week 16

    Measures biological changes in the brain

  2. Resting state fMRI

    Time frame: Twice (before intervention, post intervention):: at week 1 and week 16

    Measures biological changes in brain resting state global functional connectivity

  3. EEG- signal complexity

    Time frame: Twice (before drug administration and at peak of drug experience) during week 3

    Measures electrical signal change

Study contacts

Contact information is provided by the study sponsor or research team.

Lindsay E Golden, BS

CONTACT

[email protected]

319-384-5243

Peggy C Nopoulos, MD

CONTACT

[email protected]

319-356-1144

Sponsors and collaborators

Lead sponsor

University of Iowa

Other

Registry information

Official study title

Psilocybin vs Ketamine for Alcohol Use Disorder

Acronym: Psi or Ket

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
May 8, 2024
Registry last updated
Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.